Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CARsgen Therapeutics

http://www.carsgen.com

Latest From CARsgen Therapeutics

IASO-Innovent Tout Favourable Profile Of BCMA CAR-T

J&J partner Nanjing Legend and UniCAR developer CARsgen also race for the first China approval for BCMA targeting CAR-T therapy.

China Clinical Trials

JW Therapeutics Wins China’s Second CAR-T Approval

The approval of China's second CAR-T therapy has come amid reimbursement challenges, despite the pricing of its direct competitor being much lower than in the US. Chinese developers are pinning their hopes on rapid domestic market expansion via commercial insurance tie-ups as other CAR-Ts move through local development.

China Approvals

Asia Deal Watch: Innovent And Bolt Collaborate On Immune-Stimulating Antibody Conjugates

Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.

Deal Watch Business Strategies

US-Listed China Biotech Shares Hit By Broad China Cybersecurity Review

First DIDI, then other recently US-listed tech companies and now biotech companies are seeing share drops as China widens its cybersecurity reviews. But investors are also seeing other corrections from recent highs.

Cybersecurity China
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register